HARP Projected Dividend Yield
HARPOON THERAPEUTICS INC ( NASDAQ : HARP )Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications. 20 YEAR PERFORMANCE RESULTS |
HARP Dividend History Detail HARP Dividend News HARP Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |